Fierce Biotech November 14, 2023
Joseph Keenan

CROs Alimentiv, AcelaBio and PharmaNest are partnering in an effort to leverage precision medicine and AI-backed digital pathology tools to boost clinical trials for nonalcoholic steatohepatitis (NASH).

The triumvirate will focus on helping trial sponsors quantify the histologic effects of compounds in order to better understand underlying mechanisms in NASH-targeted therapies through the use of spatial transcriptomics and AI-powered single-fiber and single-cell digital pathology, the companies said in a joint Nov. 8 press release. Financial details of the collaboration weren’t disclosed.

Alimentiv is a CRO that specializes in gastroenterology. AcelaBio’s CRO work focuses on histopathology and precision medicine, while PharmaNest is a digital pathology and AI group specializing in the development and validation of novel histological standards for the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: AI (Artificial Intelligence), Clinical Trials, Partnerships, Pharma / Biotech, Precision Medicine, Technology, Trends
Related Articles:
Patient Dies in Gene Therapy Trial, But FDA Permits Neurogene to Proceed With Low Dose
Will Walgreens’ store closures disrupt its clinical trial aims?
Veeva Commercial Summit: Increased investment in medical affairs by pharma companies
Non-binding Guidance: Clinical Trial Diversity in Focus
NIH algorithm matches patients to clinical trials

Share This Article